Published: Dec 15, 2020
SAN DIEGO, Dec. 15, 2020 /PRNewswire/ Prometheus Biosciences, Inc. ( Prometheus ), a biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the diagnosis and treatment of inflammatory bowel disease (IBD), today announced FDA acceptance of its Investigational New Drug Application (IND) for PRA023 and that dosing has commenced in a Phase 1a clinical study in normal healthy volunteers. PRA023, the company s lead product candidate, is a humanized IgG1 monoclonal antibody (mAb) that has been shown to block tumor necrosis factor (TNF)-like ligand 1A (TL1A). TL1A is a validated clinical target that is being developed for the treatment of the two most common forms of IBD, ulcerative colitis (UC) and Crohn s disease (CD). Prometheus recently completed a $130M financing to advance novel precision medicine approaches in IBD.